历期数据

Markdown

HSA上市后警戒指南第 6 版

最终值

HSA uploaded Version 6 of the post-marketing vigilance guidance on 1 April 2026, revising scope, contact requirements, serious-adverse-event criteria, identifiable-patient examples, literature reports, lack-of-efficacy reports, clinical safety study reports and eCTD submission references guidance revision

统计期间
Version 6 uploaded 1 April 2026
适用人群
Companies responsible for post-marketing surveillance of therapeutic products and CTGTP in Singapore
分母口径
Guidance scope; not a marketing-authorisation decision and not a declaration that every adverse event is reportable
地理范围
新加坡

记录详情

发布日期
2026-04-01
指标
revision
来源版本
HSA Guidance Version 6

日期表示本记录的统计期间与适用范围。核验日期并不代表规则目前已经生效。

资料来源

  1. https://isomer-user-content.by.gov.sg/409/a6db49dc-ed7f-4e44-93ad-7fb906e7d2f8/Guidance%20for%20Industry_Post-marketing%20Vigilance%20Requirements%20for%20Therapeutic%20Products%20and%20CTGTP_V.pdf 访问日期

知识库资料截至 2026-11-22 · 知识库持续扩充中。发布数量表示现有内容,并不代表已覆盖新加坡的全部知识。 机器可读版本: JSON · sgobs.healthcare.hsa-post-marketing-vigilance-guidance-2026.revision